(514) Clinical Utility of Donor Derived Cell-Free DNA in the Multiorgan Transplantation

PurposeDonor-derived cell-free DNA (dd-cfDNA) has emerged as a reliable, noninvasive method for the detection of allograft rejection in heart transplantation (HT) patients. dd-cfDNA is widely used HT, but its utility multiorgan transplants (HT + another organ) unknown. We describe experience using transplant patients.MethodsRetrospective review all HT patients transplanted between 1998-2022 at our center that had least one collected 5/2020 and 8/2022. Patients were identified enrolled to this study. percentages quantified correlated with rejection. The variability score was calculated by variance/mean test value per person. Acute cellular (ACR) defined ISHLT grade ≥ 2R antibody mediated (AMR) > pAMR0.ResultsOf 654 levels, 35 transplant. Median age 55 years, 37.1% female; median time from 554 days [264, 1660]. 22 heart-kidney (H-K), 8 heart-liver (H-Li) 5 heart-lung (H-Lu). Of 153 samples, average levels patient 0.243 % [0.149, 0.431], 1.49 [1.02, 2.33] 0.727% [0.653, 0.790] H-K, H-Li H-Lu group, respectively. No ACR or AMR. 31 multiple drawn 4 samples [2, 6]. each 0.009, 0.263 0.0516 respectively.Conclusiondd-cfDNA chronically elevated most recipients. There high degree (particularly recipients), which may limit assay Donor-derived Retrospective pAMR0.